An interventional study of Immediate Intervention and Waitlist control in Cervical Spinal Cord Injury, sponsored by Craig Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by Craig Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Spinal Cord Injuries by Craig Hospital — 6 open to participants now, 7 under way, none of them phase 3. Spinal Cord Injuries · Craig Hospital.
Among the 21 studies in Spinal Cord Injuries by Craig Hospital, this one is the 7th largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2025, is one of 14 with no phase, and was the 19th registered.
2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.
Browse Spinal Cord Injuries studies →6 of the 21 studies in Spinal Cord Injuries by Craig Hospital are open now, in 1 country. Recruiting first, the newest first:
Craig Hospital · Sites in United States
Ages 18+ · Healthy volunteers
Craig Hospital · Sites in United States
Ages 18–89 · Men only
Craig Hospital · Sites in United States
Ages 18+
Craig Hospital · Sites in United States
Ages 18–89 · Healthy volunteers
Craig Hospital · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 4 1
First in 2006; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 46 is above the median of 24 across 1,639 interventional studies indexed under Spinal Cord Injuries.
Median enrollment 37 across the 17 interventional studies, 44 across the 4 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
Craig Hospital is the lead sponsor of 38 studies on the registry; 11 are open to participants now.
4 of the studies in Spinal Cord Injuries by Craig Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05191121Craig HospitalImproving Upper Extremity Function and Trunk Stability After Cervical Spinal Cord Injury (SCI) | 2027-02 |
| NCT06443151Craig HospitalRole of Endothelial Function in SCI CVD Risk | 2027-03-30 |
| NCT07227727Craig HospitalEndothelial Dysfunction After SCI | 2027-07-30 |
| NCT06743607Craig HospitalSpinal Stimulation for Upper Extremity Recovery in the Home | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Spinal Cord Injuries by Craig Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to evaluate the safety, feasibility, and tolerability of non-invasive spinal stimulation used in the home and/or community in combination with a functional home exercise program for the upper extremities (arm/hand function) as well as their combined impacts on changes in upper extremity function. The expected duration of participation in this study is about 31-33 hours over a 13-25-week period. Enrollees in this study will be randomly assigned to one of two groups: 1) upper extremity functional task-specific training combined with non-invasive transcutaneous spinal stimulation, or 2) waitlist control, which involves the same intervention, but with a 12-week delayed start. Participants complete initial testing (one time if in group one and three times [at weeks 0, 8, and 12] if in group two), 24 1-hour training sessions (2x/week in home with caregiver/companion support and 1x/week with research team in person or via video conference for 8 weeks), a post-treatment evaluation, and a final evaluation (4 weeks after post-treatment).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For the immediate intervention group, each participant will complete the following: * Initial baseline evaluation * 24 training sessions (3x/week for eight weeks) of UE Functional Task Practice (FTP)+TSS (two training sessions/week will be completed in the home with caregiver/companion support; the third weekly session will be conducted via videoconference with a research therapist) * Post-treatment evaluation (after eight weeks of training) and follow-up evaluation (four weeks after post-treatment evaluation). * Post-treatment and follow-up assessments will be conducted over two days: assessments completed without TSS on day one and with TSS on day two.
Behavioral: Immediate Intervention
The waitlist control group will participate in a protocol similar to the immediate intervention group, except: * 12-week waiting period before starting the active intervention. * Assessments will be completed at 0, 8, and 12 weeks before starting the active intervention to control for spontaneous recovery. * Post-treatment evaluation (after eight weeks of training) * Follow-up assessment (four weeks after the post-treatment evaluation).
Behavioral: Waitlist control
Participants will engage in a home exercise therapy program in combination with transcutaneous spinal stimulation intended to focus on the upper extremities that commences immediately after enrollment.
Participants will engage in a home exercise therapy program in combination with transcutaneous spinal stimulation intended to focus on the upper extremities that commences 12 weeks after enrollment.
Capabilities of Upper Extremity Questionnaire (CUE-Q)
The CUE-Q version 2.1 measures functional limitation and perceived difficulty of performing actions with upper extremities in individuals with tetraplegia. The CUE-Q has 32 items; each scored on a 1-to-7-point scale representing self-perceived difficulty with total scores ranging from 32 to 224 (higher scores demonstrating greater UE function) and right and left scores assessed separately
Time frame: Weeks 0, 8, 12, 21, and 25
Graded Refined Assessment of Strength, Sensibility, and Prehension (GRASSP)
This multimodal test measures sensorimotor and prehension function in three domains important in describing arm and hand function
Time frame: Weeks 0, 8, 12, 21, and 25
International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)
The ISNCSCI is a universal classification tool for SCI based on a standardized sensory and motor exam. The ISNCSCI involves a detailed examination to determine the sensory and motor levels for both the right and left sides, the overall neurological level of the injury, and the completeness of the injury as designated by the American Spinal Cord Injury Association (ASIA) Impairment Scale (AIS). The motor exam also results in a total Upper Extremity Motor Score (UEMS) ranging from 0 to 50, with higher scores indicative of greater UE strength.
Time frame: Weeks 0, 8, 12, 21, and 25
Pinch and Grasp Force
Pinch and grasp force will be measured by the Commander Echo Console with the JTech Pinch and Hand Dynamometer to quantify finger and grasp strength.
Time frame: Weeks 0, 8, 12, 21, and 25
Global Rating of Change (GRC)
The GRC assesses perceived change from an intervention. The scale is designed to quantify an individual's perceived improvement or deterioration over time. The magnitude of the change is then scored on a visual analog scale. GRC scales have been recommended for use as a core outcome measure in rehabilitation studies to improve the applicability of information from clinical trials to clinical practice.
Time frame: Weeks 8, 12, 21, and 25
Satisfaction with Treatment Scale
The Satisfaction with Treatment Scale is a 6-point scale (0=strongly disagree; 5= strongly agree) used to rate satisfaction with treatment in previous intervention studies conducted in the home environment85 and will be modified specifically to address the transcutaneous spinal stimulation (TSS) intervention.
Time frame: Weeks 8, 12, 21, and 25
Qualitative Questions
Participants and caregivers will be asked questions regarding their experience during the intervention, such as their likes and dislikes, notable changes or observations, and overall satisfaction with using TSS in their homes
Time frame: Weeks 8 and 21
Canadian Occupational Performance Measure (COPM)
The COPM is an individualized, client-centered instrument designed to measure an individual's self-perception of physical functioning and satisfaction in the activities identified as important by the client. The COPM will directly assess the true importance of functional improvements with regard to the subject's ability to perform activities of daily living and/or to function occupationally.
Time frame: Weeks 0, 8, 12, 21, and 25
International Spinal Cord Injury Quality of Life Basic Data Set (QoL-BDS) Version 2.0
This instrument measures self-reported quality of life across four domains: overall well-being, physical health, psychological health, and social life. For each domain, respondents are asked to rate their satisfaction on a 0-10 scale (0=completely dissatisfied; 10=completely satisfied).
Time frame: Weeks 0, 8, 12, 21, and 25
International Spinal Cord Injury Pain Basic Data Set (ISCIPBDS) Version 3.0
This instrument identifies pain region, pain type (e.g., nociceptive, neuropathic), and treatments used to reduce pain in addition to pain intensity on a 0-10 scale (0=no pain; 10=pain as bad as you can imagine) and interference with various aspects of the respondent's life on a 0-10 scale (0=no interference; 10=extreme interference).
Time frame: Weeks 0, 8, 12, 21, and 25
Demographic Information
Demographic information will include: age, sex, race/ethnic background, pre-injury education, employment status, marital status, and living situation.
Time frame: Week 0
Injury Characteristics
Injury information will include: date of injury, cause of injury, baseline AIS classification, and injury level.
Time frame: Week 0
Started May 2025 (actual). Primary completion is estimated for Aug 2027, 27 months after the start.
Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 27 months is below that.
Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Craig Hospital